Comparación de regímenes de linezolid, en adición a bedaquilina y pretomanida, para el manejo de tuberculosis farmacorresistente (estudio ZeNix): Lectura crítica.
Saved in:
| Title: | Comparación de regímenes de linezolid, en adición a bedaquilina y pretomanida, para el manejo de tuberculosis farmacorresistente (estudio ZeNix): Lectura crítica. |
|---|---|
| Alternate Title: | [Comparison of linezolid regimens, in addition to bedaquiline and pretomanid, for the management of drug-resistant tuberculosis (the ZeNix study): Critical reading]. |
| Authors: | Zela-Coila, Frank1 fzela@unsa.edu.pe, Cabrera-Cruzado, Carlos2,3 ccabrerac@unitru.edu.pe, Baquerizo-Quispe, Nicole Stephanie4,5 nicolebaquerizo24@gmail.com, Alvarez-Vilchez, Margarita Liz4,5 margaritaalvarezvilchez@gmail.com, Taype-Rondan, Alvaro6,7 alvaro.taype.r@gmail.com |
| Source: | Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo. 2023, Vol. 16 Issue 2, p1-11. 11p. |
| Abstract (English): | Presentation: In this article we present our critical appraisal of a randomized clinical trial published in the New England Journal of Medicine in 2022. Study conclusions: The study compares four linezolid regimens (in addition to bedaquiline and pretomanid) for the management of drug-resistant tuberculosis. Finally, it shows that the regimen of 600 mg of linezolid for 26 weeks had less frequency of therapeutic failure and adverse events (compared to giving it for fewer weeks or at higher doses). Critical comment: The article is relevant because the appropriate dose of linezolid and duration of treatment with this agent to minimize adverse effects and maintain efficacy against highly resistant tuberculosis is still unclear. Despite some limitations such as low number of participants, high loss to follow-up, and no statistical comparisons between groups, the results are relatively reliable for decision making. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Presentación: En el presente artículo exponemos nuestra valoración crítica de un ensayo clínico aleatorizado publicado en la revista New England Journal of Medicine el año 2022. Conclusiones del estudio: El estudio compara cuatro regímenes de linezolid (en adición a bedaquilina y pretomanid) para el manejo de tuberculosis farmacorresistente. Finalmente, se demuestra que el régimen de 600 mg de linezolid durante 26 semanas tuvo menos frecuencia de falla terapéutica y eventos adversos (en comparación con darlo por menos semanas o a más dosis). Comentario crítico: El artículo es relevante porque aún no es clara la dosis adecuada de linezolid y la duración del tratamiento con este agente para minimizar los efectos adversos y mantener la eficacia contra la tuberculosis altamente resistente. A pesar de algunas limitaciones como el bajo número de participantes, la alta pérdida al seguimiento, y el no realizar comparaciones estadísticas entre grupos; los resultados son relativamente confiables para la toma de decisiones. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo is the property of Cuerpo Medico del Hospital Nacional Almanzor Aguinaga Asenjo and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 174812204 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparación de regímenes de linezolid, en adición a bedaquilina y pretomanida, para el manejo de tuberculosis farmacorresistente (estudio ZeNix): Lectura crítica. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: [Comparison of linezolid regimens, in addition to bedaquiline and pretomanid, for the management of drug-resistant tuberculosis (the ZeNix study): Critical reading]. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Zela-Coila%2C+Frank%22">Zela-Coila, Frank</searchLink><relatesTo>1</relatesTo><i> fzela@unsa.edu.pe</i><br /><searchLink fieldCode="AR" term="%22Cabrera-Cruzado%2C+Carlos%22">Cabrera-Cruzado, Carlos</searchLink><relatesTo>2,3</relatesTo><i> ccabrerac@unitru.edu.pe</i><br /><searchLink fieldCode="AR" term="%22Baquerizo-Quispe%2C+Nicole+Stephanie%22">Baquerizo-Quispe, Nicole Stephanie</searchLink><relatesTo>4,5</relatesTo><i> nicolebaquerizo24@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Alvarez-Vilchez%2C+Margarita+Liz%22">Alvarez-Vilchez, Margarita Liz</searchLink><relatesTo>4,5</relatesTo><i> margaritaalvarezvilchez@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Taype-Rondan%2C+Alvaro%22">Taype-Rondan, Alvaro</searchLink><relatesTo>6,7</relatesTo><i> alvaro.taype.r@gmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+del+Cuerpo+Médico+del+Hospital+Nacional+Almanzor+Aguinaga+Asenjo%22">Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo</searchLink>. 2023, Vol. 16 Issue 2, p1-11. 11p. – Name: Abstract Label: Abstract (English) Group: Ab Data: Presentation: In this article we present our critical appraisal of a randomized clinical trial published in the New England Journal of Medicine in 2022. Study conclusions: The study compares four linezolid regimens (in addition to bedaquiline and pretomanid) for the management of drug-resistant tuberculosis. Finally, it shows that the regimen of 600 mg of linezolid for 26 weeks had less frequency of therapeutic failure and adverse events (compared to giving it for fewer weeks or at higher doses). Critical comment: The article is relevant because the appropriate dose of linezolid and duration of treatment with this agent to minimize adverse effects and maintain efficacy against highly resistant tuberculosis is still unclear. Despite some limitations such as low number of participants, high loss to follow-up, and no statistical comparisons between groups, the results are relatively reliable for decision making. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Presentación: En el presente artículo exponemos nuestra valoración crítica de un ensayo clínico aleatorizado publicado en la revista New England Journal of Medicine el año 2022. Conclusiones del estudio: El estudio compara cuatro regímenes de linezolid (en adición a bedaquilina y pretomanid) para el manejo de tuberculosis farmacorresistente. Finalmente, se demuestra que el régimen de 600 mg de linezolid durante 26 semanas tuvo menos frecuencia de falla terapéutica y eventos adversos (en comparación con darlo por menos semanas o a más dosis). Comentario crítico: El artículo es relevante porque aún no es clara la dosis adecuada de linezolid y la duración del tratamiento con este agente para minimizar los efectos adversos y mantener la eficacia contra la tuberculosis altamente resistente. A pesar de algunas limitaciones como el bajo número de participantes, la alta pérdida al seguimiento, y el no realizar comparaciones estadísticas entre grupos; los resultados son relativamente confiables para la toma de decisiones. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo is the property of Cuerpo Medico del Hospital Nacional Almanzor Aguinaga Asenjo and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=174812204 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.35434/rcmhnaaa.2023.162.1800 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Titles: – TitleFull: Comparación de regímenes de linezolid, en adición a bedaquilina y pretomanida, para el manejo de tuberculosis farmacorresistente (estudio ZeNix): Lectura crítica. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zela-Coila, Frank – PersonEntity: Name: NameFull: Cabrera-Cruzado, Carlos – PersonEntity: Name: NameFull: Baquerizo-Quispe, Nicole Stephanie – PersonEntity: Name: NameFull: Alvarez-Vilchez, Margarita Liz – PersonEntity: Name: NameFull: Taype-Rondan, Alvaro IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2023 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 22255109 Numbering: – Type: volume Value: 16 – Type: issue Value: 2 Titles: – TitleFull: Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo Type: main |
| ResultId | 1 |
